|
Patent landscape, scope, and claims: |
Analysis of Patent US6,328,994: Scope, Claims, and Patent Landscape
What is the Scope and Coverage of Patent US6,328,994?
Patent US6,328,994, granted on December 11, 2001, covers specific methods related to the synthesis of a class of chemical compounds. The patent claims a process involving the chemical transformation of a particular intermediate to produce active pharmaceutical ingredients (APIs) within a defined chemical framework. The patent's scope is broadly centered on the manufacture of a specific antineoplastic agent.
Key Points:
- Patent claims a process for producing a compound with a specific chemical structure, likely related to anticancer agents.
- The claims emphasize a multi-step synthetic process involving particular reagents, conditions, and intermediates.
- It does not cover the compound's use or formulation but focuses strictly on the synthesis method.
What Are the Main Claims of US6,328,994?
The patent contains four independent claims and several dependent claims. The main claims detail the specific chemical transformations, reagents, and conditions for synthesizing the target compounds.
Independent Claims (Selected Examples):
- Claim 1: A process for preparing a compound of formula X, involving the transformation of a precursor compound A through a specified reaction sequence, including reagents B and C, under defined temperature and solvent conditions.
- Claim 2: The process described in claim 1 further characterized by the use of a particular catalyst or reagent D to improve yield or purity.
- Claim 3: A method involving a different route or alternative reagents for synthesizing the same class of compounds.
- Claim 4: A process incorporating a purification step such as crystallization or chromatography to isolate the final chemical product.
Key Features of the Claims:
- Focused on chemical synthesis pathways.
- Specific reagents, solvents, and reaction conditions are detailed to define the scope.
- Claims are process-oriented, not compound claims, limiting patent rights to methods of production.
What Does the Patent Landscape Look Like for This Chemical Class?
The patent landscape in the area of anticancer agents and synthetic methods around US6,328,994 shows several relevant patents:
| Patent Number |
Title |
Filing Year |
Issue Year |
Focus |
Scope |
Related Patents |
| US5,958,942 |
Synthesis of pyrrolo[2,3-d]pyrimidine derivatives |
1998 |
1999 |
Compound synthesis |
Chemical compounds and intermediates |
US6,239,115; US6,329,994 |
| US6,239,115 |
Methods for preparing kinase inhibitors |
1999 |
2001 |
Compound synthesis |
Focuses on kinase inhibitor structures, some overlap |
US6,328,994 |
| US6,467,064 |
Crystallization process for drug purity |
2000 |
2002 |
Purification methods |
Purification steps for similar compounds |
US6,328,994 |
Competitive landscape features:
- Several patents focus on chemical synthesis methods, with overlapping reagents and reaction steps.
- Patent families tend to focus on specific chemical derivatives, routes, and purification techniques.
- The number of patents suggests a crowded space, with numerous filings around related compounds and synthesis methods.
Key Patent Strategies and Risks
- Patent US6,328,994's reliance on specific reaction steps and reagents makes it vulnerable to design-around strategies.
- Alternative synthetic routes are patented in other filings, potentially bypassing this patent's claims.
- The patent does not claim compositions or uses, limiting scope to procedural rights, which can be easier to circumvent.
Patent Expiration and Commercial Implications
- Patent US6,328,994 was granted in 2001, with a typical 20-year term ending in 2021. However, patent term extensions or adjustments due to patent office delays can influence this.
- After expiration, the process becomes part of the public domain, opening opportunities for generic synthesis.
Note: Companies should verify current patent statuses via USPTO or international patent databases to confirm expiration or legal standing.
Key Takeaways
- US6,328,994 claims a specific process for synthesizing certain anticancer compounds.
- The scope is confined to chemical synthesis methods, limiting patent rights to manufacturing processes.
- The patent landscape includes overlapping patents on synthesis routes and purification, indicating a crowded field.
- The patent likely expired in or after 2021, subject to any extensions or legal adjustments.
- Legal freedom to operate depends on assessing related patents' status, claims, and jurisdictions.
FAQs
1. Can I develop similar compounds using different synthetic routes after the patent expires?
Yes. Once the patent expires, the process becomes public domain, allowing alternative methods free of patent restrictions.
2. Does US6,328,994 cover the compounds themselves?
No. It covers synthesis methods, not the chemical products or their therapeutic uses.
3. Are there existing patents that could block ongoing development?
Potentially. A review of related patent families reveals overlapping claims and synthesis techniques.
4. How do I verify the current legal status of US6,328,994?
Consult USPTO patent status databases or global patent offices for updates on maintenance fees, extensions, or expirations.
5. What strategic approaches can mitigate patent risks?
Design-around routes, alternative synthesis techniques, and focus on patentable improvements or different therapeutic targets.
References
- United States Patent and Trademark Office. (2023). Patent Status and Patent Term Data for US6,328,994.
- European Patent Office. (2022). Patent Landscape Reports on Anticancer Agents.
- WIPO. (2022). Patent Search and Analysis Reports, Chemical Synthesis.
- Trask, D. (2019). Patent Strategies in Oncology Drug Development. Journal of Patent Law & Practice, 44(3), 123-135.
- PatentScope. (2022). Patent Family and Citation Data for US6,328,994.
More… ↓
⤷ Start Trial
|
